Ose Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for activation and regulation of the immune system in Immuno-Oncology and Immuno-Inflammation.

Ose Immunotherapeutics

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

DNSSEC

Engineering

Aurore Morello

Business Management

Dominique Costantini

Sr. Manager, Manufacturing Operations

Carol Ferioli

Manager Facilities and Engineering

Jim Lucie

Amandine Georges

Finance and Administration

Anne-Laure Autret-Cornet

Healthcare

Bérangère Vasseur

President JA Sollis Consulting LLC

Joan Sollis

Nicolas Poirier

Chief Operating Officer

Timothy Cooke

Chief Financial Officer

Maryvonne Hiance

Vice Chairman and Director of Public Affairs

Emile Loria

Chairman

Frederique Corallo

Chief Medical Officer

Alexis Vandier

Executive

France Companies (Top 10K)

Medical Companies With More Than $1M in Revenue (Top 10K)

Biotechnology Public Companies With More Than $1M in Revenue

Oncology Companies that Exited

OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

France 2030

Grant - OSE Immunotherapeutics

Government of France

Pays de la Loire region

European Investment Bank

Debt Financing - OSE Immunotherapeutics

Funding Round - OSE Immunotherapeutics

Bpifrance

Post-IPO Equity - OSE Immunotherapeutics

Nantes

Pays de la Loire

France

Europe

OSE Immunotherapeutics

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immuno: presents positive results in UC

OSE Immunotherapeutics Announces Positive Efficacy Results

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Provides Business and Corporate Update

Boehringer pays OSE $42M to grab new asset, expand into cardio

Hong Kong

Asia

India

Bangladesh

HTML5

F5 NGINX

Apache Server

Office 365

jQuery

Vimeo

GlobalSign

Google Fonts

Facebook Comments

Microsoft Outlook

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 10, 2024 10:12 AM	ddbd1678
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 10, 2024 10:38 AM	bf43728f
company summary	general
signals	general	Sep 10, 2024 10:12 AM	49667abb
crunchbase trigger	general	Nov 12, 2024 12:52 PM	13ad891d
crunchbase profile	general	Nov 12, 2024 2:23 PM	7a8df44d
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 2:40 PM	24828341
peers	general	Sep 10, 2024 10:12 AM	e628312f
news basic	general	Sep 10, 2024 10:12 AM	7f146332
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:OSE-IMMUNO

Ose Immunotherapeutics